Table 4.
Cause-specific mortality by airflow limitation in severe alpha 1-antitrypsin deficiency
| FEV1/FVC ratio ≥0.70
|
FEV1/FVC ratio <0.70
|
|||
|---|---|---|---|---|
| Observed/expected | SMR (95% CI) | Observed/expected | SMR (95% CI) | |
| COPD | 26/1.8 | 14.4 (9.4–21.2) | 253/3.9 | 64.9 (57.1–73.4) |
| Cardiovascular disease | 29/25.0 | 1.2 (0.8–1.7) | 47/54.6 | 0.9 (0.6–1.1) |
| Ischemic heart disease | 5/12.2 | 0.4 (0.1–0.9) | 17/28.8 | 0.6 (0.3–0.9) |
| Heart failure | 7/1.5 | 4.7 (1.9–9.6) | 11/2.8 | 3.9 (2.0–7.0) |
| Pulmonary embolism | 2/0.5 | 4.0 (0.5–14.4) | 8/0.94 | 8.5 (3.7–16.8) |
| Lung cancer | 4/3.2 | 1.3 (0.3–3.2) | 5/6.9 | 0.7 (0.2–1.7) |
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; SMR, standardized mortality ratio; CI, confidence interval.